Ooi Geraldine J, Earnest Arul, Doyle Lisa, Laurie Cheryl, Wentworth John M, Sikaris Ken, le Roux Carel W, Burton Paul R, O'Brien Paul E, Brown Wendy A
Centre for Obesity Research and Education, Department of Surgery, Central Clinical School, Monash University, Level 6, 99 Commercial Road, Melbourne, 3181, Australia.
Department of Surgery, Alfred Hospital, Melbourne, Australia.
Obes Surg. 2018 May;28(5):1351-1362. doi: 10.1007/s11695-017-3015-9.
Dyslipidemia affects up to 75% of morbidly obese individuals and is a key driver of cardiovascular disease. Weight loss is an established strategy to improve metabolic risk, including dyslipidemia. We aimed to determine weight loss goals for resolution of serum lipid abnormalities, by measuring improvements during progressive weight loss in obese individuals.
We performed a prospective cohort study of obese individuals with the metabolic syndrome undergoing adjustable gastric banding. Lipid levels were monitored monthly for 9 months, then three monthly until 24 months.
There were 101 participants included, age 47.4 ± 10.9 years with body mass index 42.6 ± 5.9 kg/m. At 24 months, total body weight loss (TBWL) was 18.3 ± 7.9%. This was associated with significant improvements in high-density lipoprotein (HDL) (1.18 vs 1.47, p < 0.001), triglyceride (2.0 vs 1.4, p < 0.001), and total cholesterol to HDL ratio (TC:HDL) (4.6 vs 3.6, p < 0.001). Over this time, progressive and linear improvements in HDL, triglycerides, and TC:HDL were seen with incremental weight loss (observed at 2.5% TBWL intervals). Significant improvements occurred after a threshold weight loss of 7.5-12.5% TBWL was achieved, with odds ratio (OR) 1.48-2.50 for normalization. These odds improved significantly with increasing weight loss (OR 18.2-30.4 with > 25% TBWL). Despite significant weight loss, there was no significant change in low-density lipoprotein (LDL).
Significant improvements in triglycerides, HDL, and TC:HDL occur after 7.5-12.5% TBWL, with ongoing benefit after greater weight loss. LDL needs to be addressed independently, as this was not observed to respond to weight loss alone.
Australian Clinical Trials Registry (ACTRN12610000049077).
血脂异常影响高达75%的病态肥胖个体,是心血管疾病的关键驱动因素。减肥是改善包括血脂异常在内的代谢风险的既定策略。我们旨在通过测量肥胖个体渐进性减肥过程中的改善情况,确定解决血清脂质异常的减肥目标。
我们对接受可调节胃束带术的代谢综合征肥胖个体进行了一项前瞻性队列研究。每月监测血脂水平9个月,然后每三个月监测一次,直至24个月。
纳入101名参与者,年龄47.4±10.9岁,体重指数42.6±5.9kg/m²。在24个月时,总体重减轻(TBWL)为18.3±7.9%。这与高密度脂蛋白(HDL)(1.18对1.47,p<0.001)、甘油三酯(2.0对1.4,p<0.001)和总胆固醇与HDL比值(TC:HDL)(4.6对3.6,p<0.001)的显著改善相关。在此期间,随着体重逐渐减轻(以2.5%TBWL间隔观察),HDL、甘油三酯和TC:HDL呈渐进性线性改善。在达到7.5 - 12.5%TBWL的阈值体重减轻后出现显著改善,正常化的比值比(OR)为1.48 - 2.50。随着体重减轻增加,这些比值显著改善(TBWL>25%时OR为18.2 - 30.4)。尽管体重显著减轻,但低密度脂蛋白(LDL)没有显著变化。
在TBWL达到7.5 - 12.5%后,甘油三酯、HDL和TC:HDL有显著改善,体重进一步减轻后仍持续受益。LDL需要单独处理,因为未观察到其仅对减肥有反应。
澳大利亚临床试验注册中心(ACTRN12610000049077)